{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:58:11Z","timestamp":1778313491362,"version":"3.51.4"},"publisher-location":"Cham","reference-count":171,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030685096","type":"print"},{"value":"9783030685102","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/164_2020_384","type":"book-chapter","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T14:02:47Z","timestamp":1598536967000},"page":"229-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches"],"prefix":"10.1007","author":[{"given":"Pablo","family":"Duarte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"384_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.brainres.2007.11.051","volume":"1191","author":"LM Aguiar","year":"2008","unstructured":"Aguiar LM et al (2008) CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats. Brain Res 1191:192\u2013199","journal-title":"Brain Res"},{"issue":"5","key":"384_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0278-5846(03)00117-9","volume":"27","author":"S Akhondzadeh","year":"2003","unstructured":"Akhondzadeh S et al (2003) Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 27(5):841\u2013845","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"384_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1192\/bjp.bp.115.173930","volume":"210","author":"M Alda","year":"2017","unstructured":"Alda M et al (2017) Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatry 210(1):54\u201360","journal-title":"Br J Psychiatry"},{"issue":"19","key":"384_CR4","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1523\/JNEUROSCI.0925-08.2008","volume":"28","author":"N Alia-Klein","year":"2008","unstructured":"Alia-Klein N et al (2008) Brain monoamine oxidase A activity predicts trait aggression. J Neurosci 28(19):5099\u20135104","journal-title":"J Neurosci"},{"issue":"11","key":"384_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/BF00978365","volume":"18","author":"MC Anderson","year":"1993","unstructured":"Anderson MC et al (1993) Monoamine oxidase inhibitors and the cheese effect. Neurochem Res 18(11):1145\u20131149","journal-title":"Neurochem Res"},{"issue":"3","key":"384_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.neurobiolaging.2014.10.026","volume":"36","author":"O Bar-Am","year":"2015","unstructured":"Bar-Am O et al (2015) Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A\/monoamine oxidase-B inhibitor in animal models of Parkinson\u2019s disease and aging. Neurobiol Aging 36(3):1529\u20131542","journal-title":"Neurobiol Aging"},{"issue":"1","key":"384_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bbr.2010.07.033","volume":"216","author":"JK Barbiero","year":"2011","unstructured":"Barbiero JK et al (2011) Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson\u2019s disease. Behav Brain Res 216(1):186\u2013192","journal-title":"Behav Brain Res"},{"issue":"8","key":"384_CR8","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/ene.12724","volume":"22","author":"P Barone","year":"2015","unstructured":"Barone P et al (2015) A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients. Eur J Neurol 22(8):1184\u20131191","journal-title":"Eur J Neurol"},{"issue":"1-2","key":"384_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2014.12.039","volume":"349","author":"M Bartolo","year":"2015","unstructured":"Bartolo M et al (2015) An explorative study regarding the effect of l-deprenyl on cognitive and functional recovery in patients after stroke. J Neurol Sci 349(1-2):117\u2013123","journal-title":"J Neurol Sci"},{"issue":"4","key":"384_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/0009-9236(95)90058-6","volume":"58","author":"I Berlin","year":"1995","unstructured":"Berlin I et al (1995) A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 58(4):444\u2013452","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"384_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1527-3458.1999.tb00093.x","volume":"5","author":"MD Berry","year":"1999","unstructured":"Berry MD (1999) R-2HMP: an orally active agent combining independent antiapoptotic and MAO-B-inhibitory activities. CNS Drug Rev 5(2):105\u2013124","journal-title":"CNS Drug Rev"},{"key":"384_CR12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2147\/TCRM.S139545","volume":"14","author":"S Bette","year":"2018","unstructured":"Bette S et al (2018) Safinamide in the management of patients with Parkinson\u2019s disease not stabilized on levodopa: a review of the current clinical evidence. Ther Clin Risk Manag 14:1737\u20131745","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"384_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nsb732","volume":"9","author":"C Binda","year":"2002","unstructured":"Binda C et al (2002) Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 9(1):22\u201326","journal-title":"Nat Struct Biol"},{"issue":"17","key":"384_CR14","doi-asserted-by":"publisher","first-page":"9750","DOI":"10.1073\/pnas.1633804100","volume":"100","author":"C Binda","year":"2003","unstructured":"Binda C et al (2003) Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci U S A 100(17):9750\u20139755","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"384_CR15","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1021\/jm031087c","volume":"47","author":"C Binda","year":"2004","unstructured":"Binda C et al (2004) Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem 47(7):1767\u20131774","journal-title":"J Med Chem"},{"issue":"26","key":"384_CR16","doi-asserted-by":"publisher","first-page":"8148","DOI":"10.1021\/jm0506266","volume":"48","author":"C Binda","year":"2005","unstructured":"Binda C et al (2005) Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. J Med Chem 48(26):8148\u20138154","journal-title":"J Med Chem"},{"issue":"23","key":"384_CR17","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1021\/jm070677y","volume":"50","author":"C Binda","year":"2007","unstructured":"Binda C et al (2007) Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 50(23):5848\u20135852","journal-title":"J Med Chem"},{"issue":"1","key":"384_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/ml200196p","volume":"3","author":"C Binda","year":"2011","unstructured":"Binda C et al (2011a) Molecular insights into human monoamine oxidase B inhibition by the glitazone anti-diabetes drugs. ACS Med Chem Lett 3(1):39\u201342","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"384_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/jm101359c","volume":"54","author":"C Binda","year":"2011","unstructured":"Binda C et al (2011b) Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex. J Med Chem 54(3):909\u2013912","journal-title":"J Med Chem"},{"key":"384_CR20","first-page":"91","volume":"9","author":"J Blesa","year":"2015","unstructured":"Blesa J et al (2015) Oxidative stress and Parkinson\u2019s disease. Front Neuroanat 9:91","journal-title":"Front Neuroanat"},{"key":"384_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.expneurol.2017.11.009","volume":"300","author":"JM Bonato","year":"2018","unstructured":"Bonato JM et al (2018) Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson\u2019s disease in rats. Exp Neurol 300:188\u2013200","journal-title":"Exp Neurol"},{"issue":"47","key":"384_CR22","doi-asserted-by":"publisher","first-page":"36849","DOI":"10.1074\/jbc.M110.169482","volume":"285","author":"D Bonivento","year":"2010","unstructured":"Bonivento D et al (2010) Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J Biol Chem 285(47):36849\u201336856","journal-title":"J Biol Chem"},{"issue":"10","key":"384_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R et al (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord 29(10):1273\u20131280","journal-title":"Mov Disord"},{"issue":"3","key":"384_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/jpet.117.241653","volume":"362","author":"E Borroni","year":"2017","unstructured":"Borroni E et al (2017) Sembragiline: a novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer\u2019s disease. J Pharmacol Exp Ther 362(3):413\u2013423","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"384_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/cells7080091","volume":"7","author":"O Buneeva","year":"2018","unstructured":"Buneeva O et al (2018) The effect of neurotoxin MPTP and neuroprotector isatin on the profile of ubiquitinated brain mitochondrial proteins. Cell 7(8):91","journal-title":"Cell"},{"issue":"11","key":"384_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/j.1532-5415.1993.tb07306.x","volume":"41","author":"WJ Burke","year":"1993","unstructured":"Burke WJ et al (1993) L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 41(11):1219\u20131225","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"384_CR27","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3892\/mmr.2014.2040","volume":"9","author":"Z Cai","year":"2014","unstructured":"Cai Z (2014) Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer\u2019s disease (Review). Mol Med Rep 9(5):1533\u20131541","journal-title":"Mol Med Rep"},{"issue":"4","key":"384_CR28","first-page":"306","volume":"12","author":"N Campi","year":"1990","unstructured":"Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 12(4):306\u2013314","journal-title":"Clin Ther"},{"key":"384_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.neuroscience.2011.07.046","volume":"194","author":"AR Carta","year":"2011","unstructured":"Carta AR et al (2011) Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson\u2019s disease model. Neuroscience 194:250\u2013261","journal-title":"Neuroscience"},{"key":"384_CR30","first-page":"CD006661","volume":"4","author":"R Caslake","year":"2009","unstructured":"Caslake R et al (2009) Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson\u2019s disease. Cochrane Database Syst Rev 4:CD006661","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"384_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1163\/156856003765764353","volume":"11","author":"K Castagnoli","year":"2003","unstructured":"Castagnoli K et al (2003) Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration. Inflammopharmacology 11(2):183\u2013188","journal-title":"Inflammopharmacology"},{"issue":"4","key":"384_CR32","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","volume":"35","author":"C Cattaneo","year":"2018","unstructured":"Cattaneo C et al (2018) Long-term efficacy of safinamide on Parkinson\u2019s disease chronic pain. Adv Ther 35(4):515\u2013522","journal-title":"Adv Ther"},{"key":"384_CR33","first-page":"114","volume":"7","author":"JY Chen","year":"2013","unstructured":"Chen JY et al (2013) Dopamine imbalance in Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility. Front Neurosci 7:114","journal-title":"Front Neurosci"},{"issue":"Suppl 2","key":"384_CR34","first-page":"S51","volume":"16","author":"G Chouinard","year":"1993","unstructured":"Chouinard G et al (1993) Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clin Neuropharmacol 16(Suppl 2):S51\u2013S54","journal-title":"Clin Neuropharmacol"},{"issue":"24","key":"384_CR35","doi-asserted-by":"publisher","first-page":"7416","DOI":"10.1016\/j.bmc.2011.10.049","volume":"19","author":"E Coelho Cerqueira","year":"2011","unstructured":"Coelho Cerqueira E et al (2011) Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO. Bioorg Med Chem 19(24):7416\u20137424","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"384_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.molmed.2004.03.007","volume":"10","author":"F Cote","year":"2004","unstructured":"Cote F et al (2004) Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 10(5):232\u2013238","journal-title":"Trends Mol Med"},{"key":"384_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-2-14","volume":"2","author":"E Croisier","year":"2005","unstructured":"Croisier E et al (2005) Microglial inflammation in the Parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2:14","journal-title":"J Neuroinflammation"},{"issue":"1","key":"384_CR38","first-page":"253","volume":"277","author":"O Curet","year":"1996","unstructured":"Curet O et al (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther 277(1):253\u2013264","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"384_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0304-3940(02)00614-6","volume":"329","author":"B Cutillas","year":"2002","unstructured":"Cutillas B, Ambrosio S, Unzeta M (2002) Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci Lett 329(2):165\u2013168","journal-title":"Neurosci Lett"},{"key":"384_CR40","first-page":"31","volume":"26","author":"M Da Prada","year":"1988","unstructured":"Da Prada M et al (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl 26:31\u201356","journal-title":"J Neural Transm Suppl"},{"key":"384_CR41","doi-asserted-by":"publisher","first-page":"e2727","DOI":"10.7717\/peerj.2727","volume":"4","author":"V Dakic","year":"2016","unstructured":"Dakic V et al (2016) Harmine stimulates proliferation of human neural progenitors. PeerJ 4:e2727","journal-title":"PeerJ"},{"issue":"6","key":"384_CR42","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1080\/07391102.2017.1325405","volume":"36","author":"S Dasgupta","year":"2018","unstructured":"Dasgupta S et al (2018) Recognition dynamics of dopamine to human monoamine oxidase B: role of Leu171\/Gln206 and conserved water molecules in the active site cavity. J Biomol Struct Dyn 36(6):1439\u20131462","journal-title":"J Biomol Struct Dyn"},{"issue":"36","key":"384_CR43","doi-asserted-by":"publisher","first-page":"12684","DOI":"10.1073\/pnas.0505975102","volume":"102","author":"L De Colibus","year":"2005","unstructured":"De Colibus L et al (2005) Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci U S A 102(36):12684\u201312689","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"384_CR44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1570159X14666151120123025","volume":"14","author":"J Dong","year":"2016","unstructured":"Dong J et al (2016) Current pharmaceutical treatments and alternative therapies of Parkinson\u2019s disease. Curr Neuropharmacol 14(4):339\u2013355","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"384_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2016.1260189","volume":"49","author":"RG Dos Santos","year":"2017","unstructured":"Dos Santos RG, Hallak JE (2017) Effects of the natural beta-carboline alkaloid harmine, a main constituent of Ayahuasca, in memory and in the hippocampus: a systematic literature review of preclinical studies. J Psychoactive Drugs 49(1):1\u201310","journal-title":"J Psychoactive Drugs"},{"key":"384_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-981-10-7757-9_5","volume":"87","author":"DE Edmondson","year":"2018","unstructured":"Edmondson DE, Binda C (2018) Monoamine oxidases. Subcell Biochem 87:117\u2013139","journal-title":"Subcell Biochem"},{"issue":"20","key":"384_CR47","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1021\/bi900413g","volume":"48","author":"DE Edmondson","year":"2009","unstructured":"Edmondson DE et al (2009) Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 48(20):4220\u20134230","journal-title":"Biochemistry"},{"issue":"6","key":"384_CR48","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.bbapap.2014.03.006","volume":"1844","author":"G Esteban","year":"2014","unstructured":"Esteban G et al (2014) Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer\u2019s disease. Biochim Biophys Acta 1844(6):1104\u20131110","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"384_CR49","first-page":"461","volume":"20","author":"B Evranos-Aksoz","year":"2017","unstructured":"Evranos-Aksoz B et al (2017) New human monoamine oxidase A inhibitors with potential anti-depressant activity: design, synthesis, biological screening and evaluation of pharmacological activity. Comb Chem High Throughput Screen 20(6):461\u2013473","journal-title":"Comb Chem High Throughput Screen"},{"issue":"6","key":"384_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2217\/nmt.15.46","volume":"5","author":"M Fabbri","year":"2015","unstructured":"Fabbri M et al (2015) Clinical pharmacology review of safinamide for the treatment of Parkinson\u2019s disease. Neurodegener Dis Manag 5(6):481\u2013496","journal-title":"Neurodegener Dis Manag"},{"key":"384_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ibror.2019.01.001","volume":"6","author":"OJ Fasipe","year":"2019","unstructured":"Fasipe OJ (2019) The emergence of new antidepressants for clinical use: agomelatine paradox versus other novel agents. IBRO Rep 6:95\u2013110","journal-title":"IBRO Rep"},{"issue":"3","key":"384_CR52","first-page":"234","volume":"24","author":"V Filip","year":"1999","unstructured":"Filip V, Kolibas E (1999) Selegiline in the treatment of Alzheimer\u2019s disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci 24(3):234\u2013243","journal-title":"J Psychiatry Neurosci"},{"issue":"2","key":"384_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","volume":"143","author":"JP Finberg","year":"2014","unstructured":"Finberg JP (2014) Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther 143(2):133\u2013152","journal-title":"Pharmacol Ther"},{"key":"384_CR54","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fphar.2016.00340","volume":"7","author":"JP Finberg","year":"2016","unstructured":"Finberg JP, Rabey JM (2016) Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol 7:340","journal-title":"Front Pharmacol"},{"issue":"4","key":"384_CR55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0197-4580(97)00037-7","volume":"18","author":"JS Fowler","year":"1997","unstructured":"Fowler JS et al (1997) Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 18(4):431\u2013435","journal-title":"Neurobiol Aging"},{"issue":"3","key":"384_CR56","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/npp.2009.167","volume":"35","author":"JS Fowler","year":"2010","unstructured":"Fowler JS et al (2010) Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology 35(3):623\u2013631","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"384_CR57","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1471-4159.2005.03341.x","volume":"95","author":"S Gal","year":"2005","unstructured":"Gal S et al (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95(1):79\u201388","journal-title":"J Neurochem"},{"issue":"2","key":"384_CR58","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12640-009-9128-8","volume":"18","author":"S Gal","year":"2010","unstructured":"Gal S, Abassi ZA, Youdim MB (2010) Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox Res 18(2):143\u2013150","journal-title":"Neurotox Res"},{"key":"384_CR59","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.expneurol.2016.01.019","volume":"278","author":"M Garcia-Miralles","year":"2016","unstructured":"Garcia-Miralles M et al (2016) Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Exp Neurol 278:4\u201310","journal-title":"Exp Neurol"},{"issue":"11","key":"384_CR60","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.biopsych.2005.11.016","volume":"59","author":"PK Gillman","year":"2006","unstructured":"Gillman PK (2006) A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59(11):1046\u20131051","journal-title":"Biol Psychiatry"},{"issue":"2","key":"384_CR61","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12640-015-9574-4","volume":"29","author":"S Golko-Perez","year":"2016","unstructured":"Golko-Perez S et al (2016) Additive neuroprotective effects of the multifunctional iron chelator M30 with enriched diet in a mouse model of amyotrophic lateral sclerosis. Neurotox Res 29(2):208\u2013217","journal-title":"Neurotox Res"},{"issue":"6","key":"384_CR62","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4103\/0253-7613.121266","volume":"45","author":"ND Grover","year":"2013","unstructured":"Grover ND et al (2013) Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson\u2019s disease. Indian J Pharmacol 45(6):547\u2013555","journal-title":"Indian J Pharmacol"},{"key":"384_CR63","first-page":"321","volume":"41","author":"S Henriot","year":"1994","unstructured":"Henriot S et al (1994) Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. J Neural Transm Suppl 41:321\u2013325","journal-title":"J Neural Transm Suppl"},{"issue":"12","key":"384_CR64","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3390\/molecules22122076","volume":"22","author":"M Hoon","year":"2017","unstructured":"Hoon M et al (2017) The design and evaluation of an l-dopa-lazabemide prodrug for the treatment of Parkinson\u2019s disease. Molecules 22(12):2076","journal-title":"Molecules"},{"issue":"31","key":"384_CR65","doi-asserted-by":"publisher","first-page":"28612","DOI":"10.1074\/jbc.M303712200","volume":"278","author":"F Hubalek","year":"2003","unstructured":"Hubalek F, Pohl J, Edmondson DE (2003) Structural comparison of human monoamine oxidases A and B: mass spectrometry monitoring of cysteine reactivities. J Biol Chem 278(31):28612\u201328618","journal-title":"J Biol Chem"},{"issue":"16","key":"384_CR66","doi-asserted-by":"publisher","first-page":"15761","DOI":"10.1074\/jbc.M500949200","volume":"280","author":"F Hubalek","year":"2005","unstructured":"Hubalek F et al (2005) Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem 280(16):15761\u201315766","journal-title":"J Biol Chem"},{"issue":"1","key":"384_CR67","first-page":"39","volume":"21","author":"C Huuskonen","year":"2019","unstructured":"Huuskonen C et al (2019) Monoamine oxidase A inhibition protects the myocardium after experimental acute volume overload. Anatol J Cardiol 21(1):39\u201345","journal-title":"Anatol J Cardiol"},{"issue":"6","key":"384_CR68","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.parkreldis.2014.02.024","volume":"20","author":"J Jankovic","year":"2014","unstructured":"Jankovic J et al (2014) Symptomatic efficacy of rasagiline monotherapy in early Parkinson\u2019s disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord 20(6):640\u2013643","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"384_CR69","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nm.3639","volume":"20","author":"S Jo","year":"2014","unstructured":"Jo S et al (2014) GABA from reactive astrocytes impairs memory in mouse models of Alzheimer\u2019s disease. Nat Med 20(8):886\u2013896","journal-title":"Nat Med"},{"key":"384_CR70","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neuint.2016.06.012","volume":"99","author":"LA Justo","year":"2016","unstructured":"Justo LA et al (2016) Effects and mechanism of action of isatin, a MAO inhibitor, on in vivo striatal dopamine release. Neurochem Int 99:147\u2013157","journal-title":"Neurochem Int"},{"issue":"1","key":"384_CR71","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1161\/CIRCRESAHA.109.198366","volume":"106","author":"N Kaludercic","year":"2010","unstructured":"Kaludercic N et al (2010) Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res 106(1):193\u2013202","journal-title":"Circ Res"},{"issue":"2","key":"384_CR72","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/ars.2012.4616","volume":"20","author":"N Kaludercic","year":"2014","unstructured":"Kaludercic N et al (2014) Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal 20(2):267\u2013280","journal-title":"Antioxid Redox Signal"},{"issue":"7","key":"384_CR73","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00702-003-0828-6","volume":"110","author":"BP Kennedy","year":"2003","unstructured":"Kennedy BP et al (2003) Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer\u2019s disease. J Neural Transm 110(7):789\u2013801","journal-title":"J Neural Transm"},{"issue":"10","key":"384_CR74","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1016\/j.bmc.2005.12.057","volume":"14","author":"AA Khalil","year":"2006","unstructured":"Khalil AA, Davies B, Castagnoli N Jr (2006) Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorg Med Chem 14(10):3392\u20133398","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"384_CR75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/WNF.0b013e31823b1da8","volume":"35","author":"A Korchounov","year":"2012","unstructured":"Korchounov A, Winter Y, Rossy W (2012) Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol 35(3):121\u2013124","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"384_CR76","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12035-012-8304-7","volume":"46","author":"L Kupershmidt","year":"2012","unstructured":"Kupershmidt L et al (2012) Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer\u2019s-like neuropathology and age-related alterations in mice. Mol Neurobiol 46(1):217\u2013220","journal-title":"Mol Neurobiol"},{"issue":"1","key":"384_CR77","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/archneur.55.1.93","volume":"55","author":"DJ Lange","year":"1998","unstructured":"Lange DJ et al (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 55(1):93\u201396","journal-title":"Arch Neurol"},{"issue":"4669","key":"384_CR78","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.6332378","volume":"225","author":"JW Langston","year":"1984","unstructured":"Langston JW et al (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225(4669):1480\u20131482","journal-title":"Science"},{"issue":"3","key":"384_CR79","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0304-3940(97)00170-5","volume":"224","author":"W Le","year":"1997","unstructured":"Le W et al (1997) (\u2212)-Deprenyl protection of 1-methyl-4 phenylpyridinium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett 224(3):197\u2013200","journal-title":"Neurosci Lett"},{"issue":"5","key":"384_CR80","first-page":"527","volume":"3","author":"KC Lee","year":"2007","unstructured":"Lee KC, Chen JJ (2007) Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat 3(5):527\u2013537","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"384_CR81","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.toxlet.2012.07.016","volume":"213","author":"EY Lee","year":"2012","unstructured":"Lee EY et al (2012) Rosiglitazone, a PPAR-gamma agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats. Toxicol Lett 213(3):332\u2013344","journal-title":"Toxicol Lett"},{"issue":"15","key":"384_CR82","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1021\/bi051847g","volume":"45","author":"M Li","year":"2006","unstructured":"Li M et al (2006) Functional role of the \u201caromatic cage\u201d in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins. Biochemistry 45(15):4775\u20134784","journal-title":"Biochemistry"},{"issue":"Pt B","key":"384_CR83","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.pnpbp.2017.06.012","volume":"79","author":"F Liu","year":"2017","unstructured":"Liu F et al (2017a) Harmine produces antidepressant-like effects via restoration of astrocytic functions. Prog Neuro-Psychopharmacol Biol Psychiatry 79(Pt B):258\u2013267","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"3","key":"384_CR84","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.bbrc.2017.05.126","volume":"489","author":"X Liu","year":"2017","unstructured":"Liu X et al (2017b) Harmine is an inflammatory inhibitor through the suppression of NF-kappaB signaling. Biochem Biophys Res Commun 489(3):332\u2013338","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"384_CR85","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s12035-019-01788-2","volume":"57","author":"Y Liu","year":"2019","unstructured":"Liu Y et al (2019) Attenuation of ischemic stroke-caused brain injury by a monoamine oxidase inhibitor involves improved proteostasis and reduced neuroinflammation. Mol Neurobiol 57(2):937\u2013948","journal-title":"Mol Neurobiol"},{"issue":"3","key":"384_CR86","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0893-133X(98)00075-X","volume":"20","author":"F Lotufo-Neto","year":"1999","unstructured":"Lotufo-Neto F, Trivedi M, Thase ME (1999) Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 20(3):226\u2013247","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"384_CR87","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1474-4422(18)30176-5","volume":"17","author":"AC Ludolph","year":"2018","unstructured":"Ludolph AC et al (2018) Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol 17(8):681\u2013688","journal-title":"Lancet Neurol"},{"issue":"4","key":"384_CR88","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.pharep.2018.11.005","volume":"71","author":"MMF Machado","year":"2019","unstructured":"Machado MMF et al (2019) PPAR-gamma agonist pioglitazone reduces microglial proliferation and NF-kappaB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson\u2019s disease. Pharmacol Rep 71(4):556\u2013564","journal-title":"Pharmacol Rep"},{"issue":"2","key":"384_CR89","doi-asserted-by":"publisher","first-page":"e1616","DOI":"10.1371\/journal.pone.0001616","volume":"3","author":"JK Mallajosyula","year":"2008","unstructured":"Mallajosyula JK et al (2008) MAO-B elevation in mouse brain astrocytes results in Parkinson\u2019s pathology. PLoS One 3(2):e1616","journal-title":"PLoS One"},{"key":"384_CR90","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fnins.2016.00294","volume":"10","author":"J Marco-Contelles","year":"2016","unstructured":"Marco-Contelles J et al (2016) ASS234, as a new multi-target directed propargylamine for Alzheimer\u2019s disease therapy. Front Neurosci 10:294","journal-title":"Front Neurosci"},{"issue":"2","key":"384_CR91","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.expneurol.2012.02.017","volume":"235","author":"HL Martin","year":"2012","unstructured":"Martin HL et al (2012) Pharmacological manipulation of peroxisome proliferator-activated receptor gamma (PPARgamma) reveals a role for anti-oxidant protection in a model of Parkinson\u2019s disease. Exp Neurol 235(2):528\u2013538","journal-title":"Exp Neurol"},{"issue":"1","key":"384_CR92","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.2042-7158.2003.tb02430.x","volume":"55","author":"M Mawhinney","year":"2003","unstructured":"Mawhinney M, Cole D, Azzaro AJ (2003) Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 55(1):27\u201334","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"384_CR93","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1478-811X-11-34","volume":"11","author":"J Meiser","year":"2013","unstructured":"Meiser J, Weindl D, Hiller K (2013) Complexity of dopamine metabolism. Cell Commun Signal 11(1):34","journal-title":"Cell Commun Signal"},{"issue":"11","key":"384_CR94","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/archpsyc.63.11.1209","volume":"63","author":"JH Meyer","year":"2006","unstructured":"Meyer JH et al (2006) Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63(11):1209\u20131216","journal-title":"Arch Gen Psychiatry"},{"issue":"24","key":"384_CR95","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1111\/j.1742-4658.2011.08386.x","volume":"278","author":"EM Milczek","year":"2011","unstructured":"Milczek EM et al (2011) The \u2018gating\u2019 residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. FEBS J 278(24):4860\u20134869","journal-title":"FEBS J"},{"issue":"12","key":"384_CR96","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1177\/0269881114553646","volume":"28","author":"M Morais","year":"2014","unstructured":"Morais M et al (2014) The effects of chronic stress on hippocampal adult neurogenesis and dendritic plasticity are reversed by selective MAO-A inhibition. J Psychopharmacol 28(12):1178\u20131183","journal-title":"J Psychopharmacol"},{"issue":"5","key":"384_CR97","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/17425255.2019.1607292","volume":"15","author":"T Muller","year":"2019","unstructured":"Muller T, Mohr JD (2019) Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson\u2019s disease: current status. Expert Opin Drug Metab Toxicol 15(5):429\u2013435","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"384_CR98","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00702-012-0927-3","volume":"120","author":"T Muller","year":"2013","unstructured":"Muller T et al (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson\u2019s disease. J Neural Transm 120(5):761\u2013765","journal-title":"J Neural Transm"},{"issue":"10","key":"384_CR99","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mds.26286","volume":"30","author":"M Murata","year":"2015","unstructured":"Murata M et al (2015) Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study. Mov Disord 30(10):1343\u20131350","journal-title":"Mov Disord"},{"issue":"1","key":"384_CR100","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ncn3.12026","volume":"4","author":"M Murata","year":"2016","unstructured":"Murata M et al (2016) Randomized placebo-controlled trial of zonisamide in patients with Parkinson\u2019s disease. Neurol Clin Neurosci 4(1):10\u201315","journal-title":"Neurol Clin Neurosci"},{"issue":"8","key":"384_CR101","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","volume":"90","author":"M Murata","year":"2018","unstructured":"Murata M et al (2018) Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology 90(8):e664\u2013e672","journal-title":"Neurology"},{"issue":"4","key":"384_CR102","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1600-0404.1997.tb00101.x","volume":"95","author":"VV Myllyla","year":"1997","unstructured":"Myllyla VV et al (1997) Selegiline as the primary treatment of Parkinson\u2019s disease--a long-term double-blind study. Acta Neurol Scand 95(4):211\u2013218","journal-title":"Acta Neurol Scand"},{"key":"384_CR103","first-page":"53","volume":"71","author":"T Nagatsu","year":"2006","unstructured":"Nagatsu T, Sawada M (2006) Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson\u2019s disease: possible implications of glial cells. J Neural Transm Suppl 71:53\u201365","journal-title":"J Neural Transm Suppl"},{"issue":"49","key":"384_CR104","doi-asserted-by":"publisher","first-page":"14839","DOI":"10.1021\/bi011113d","volume":"40","author":"RK Nandigama","year":"2001","unstructured":"Nandigama RK, Miller JR, Edmondson DE (2001) Loss of serotonin oxidation as a component of the altered substrate specificity in the Y444F mutant of recombinant human liver MAO A. Biochemistry 40(49):14839\u201314846","journal-title":"Biochemistry"},{"issue":"4","key":"384_CR105","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3233\/JAD-161309","volume":"58","author":"S Nave","year":"2017","unstructured":"Nave S et al (2017) Sembragiline in moderate Alzheimer\u2019s disease: results of a randomized, double-blind, placebo-controlled phase II trial (MAyflOwer RoAD). J Alzheimers Dis 58(4):1217\u20131228","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"384_CR106","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","volume":"14","author":"L Neurol","year":"2015","unstructured":"Neurol L (2015) Pioglitazone in early Parkinson\u2019s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol 14(8):795\u2013803","journal-title":"Lancet Neurol"},{"key":"384_CR107","first-page":"8626783","volume":"2018","author":"H Nishijima","year":"2018","unstructured":"Nishijima H et al (2018) Zonisamide enhances motor effects of levodopa, not of apomorphine, in a rat model of Parkinson\u2019s disease. Parkinsons Dis 2018:8626783","journal-title":"Parkinsons Dis"},{"issue":"1","key":"384_CR108","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0022-510X(02)00342-8","volume":"206","author":"A Ogata","year":"2003","unstructured":"Ogata A et al (2003) Isatin, an endogenous MAO inhibitor, improves bradykinesia and dopamine levels in a rat model of Parkinson\u2019s disease induced by Japanese encephalitis virus. J Neurol Sci 206(1):79\u201383","journal-title":"J Neurol Sci"},{"key":"384_CR109","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neures.2017.04.003","volume":"122","author":"M Oki","year":"2017","unstructured":"Oki M et al (2017) Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats. Neurosci Res 122:45\u201350","journal-title":"Neurosci Res"},{"issue":"13","key":"384_CR110","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med 361(13):1268\u20131278","journal-title":"N Engl J Med"},{"issue":"3","key":"384_CR111","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1007\/s12035-014-8974-4","volume":"52","author":"J Ooi","year":"2015","unstructured":"Ooi J, Hayden MR, Pouladi MA (2015) Inhibition of excessive monoamine oxidase A\/B activity protects against stress-induced neuronal death in Huntington disease. Mol Neurobiol 52(3):1850\u20131861","journal-title":"Mol Neurobiol"},{"issue":"8","key":"384_CR112","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.bcp.2009.04.034","volume":"78","author":"M Oz","year":"2009","unstructured":"Oz M, Lorke DE, Petroianu GA (2009) Methylene blue and Alzheimer\u2019s disease. Biochem Pharmacol 78(8):927\u2013932","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"384_CR113","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11481-012-9358-z","volume":"7","author":"R Panarsky","year":"2012","unstructured":"Panarsky R, Luques L, Weinstock M (2012) Anti-inflammatory effects of ladostigil and its metabolites in aged rat brain and in microglial cells. J Neuroimmune Pharmacol 7(2):488\u2013498","journal-title":"J Neuroimmune Pharmacol"},{"issue":"3","key":"384_CR114","doi-asserted-by":"publisher","first-page":"eaav0316","DOI":"10.1126\/sciadv.aav0316","volume":"5","author":"JH Park","year":"2019","unstructured":"Park JH et al (2019) Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer\u2019s disease. Sci Adv 5(3):eaav0316","journal-title":"Sci Adv"},{"issue":"20","key":"384_CR115","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","volume":"321","author":"G Parkinson Study","year":"1989","unstructured":"Parkinson Study G (1989) Effect of deprenyl on the progression of disability in early Parkinson\u2019s disease. N Engl J Med 321(20):1364\u20131371","journal-title":"N Engl J Med"},{"issue":"4","key":"384_CR116","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archneur.1994.00540160036006","volume":"51","author":"G Parkinson Study","year":"1994","unstructured":"Parkinson Study G (1994) A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson\u2019s disease. Arch Neurol 51(4):342\u2013347","journal-title":"Arch Neurol"},{"issue":"12","key":"384_CR117","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","author":"G Parkinson Study","year":"2002","unstructured":"Parkinson Study G (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 59(12):1937\u20131943","journal-title":"Arch Neurol"},{"issue":"4","key":"384_CR118","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archneur.61.4.561","volume":"61","author":"G Parkinson Study","year":"2004","unstructured":"Parkinson Study G (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61(4):561\u2013566","journal-title":"Arch Neurol"},{"issue":"3","key":"384_CR119","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0197-0186(02)00091-8","volume":"42","author":"V Perez","year":"2003","unstructured":"Perez V, Unzeta M (2003) PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57\/BL6 mice. Neurochem Int 42(3):221\u2013229","journal-title":"Neurochem Int"},{"issue":"4","key":"384_CR120","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/sj.bjp.0702600","volume":"127","author":"V P\u00e9rez","year":"1999","unstructured":"P\u00e9rez V et al (1999) Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br J Pharmacol 127(4):869\u2013876","journal-title":"Br J Pharmacol"},{"issue":"2","key":"384_CR121","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3233\/JAD-143126","volume":"47","author":"LS Pimentel","year":"2015","unstructured":"Pimentel LS et al (2015) The multi-target drug m30 shows pro-cognitive and anti-inflammatory effects in a rat model of Alzheimer\u2019s disease. J Alzheimers Dis 47(2):373\u2013383","journal-title":"J Alzheimers Dis"},{"key":"384_CR122","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13024-016-0090-7","volume":"11","author":"M Pinto","year":"2016","unstructured":"Pinto M et al (2016) Pioglitazone ameliorates the phenotype of a novel Parkinson\u2019s disease mouse model by reducing neuroinflammation. Mol Neurodegener 11:25","journal-title":"Mol Neurodegener"},{"key":"384_CR123","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"384_CR124","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1468-1331.1999.tb00007.x","volume":"6","author":"H Przuntek","year":"1999","unstructured":"Przuntek H et al (1999) SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 6(2):141\u2013150","journal-title":"Eur J Neurol"},{"issue":"6","key":"384_CR125","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","volume":"23","author":"JM Rabey","year":"2000","unstructured":"Rabey JM et al (2000) Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson\u2019s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23(6):324\u2013330","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"384_CR126","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4103\/0019-5545.82567","volume":"53","author":"CT Ramachandraih","year":"2011","unstructured":"Ramachandraih CT et al (2011) Antidepressants: from MAOIs to SSRIs and more. Indian J Psychiatry 53(2):180\u2013182","journal-title":"Indian J Psychiatry"},{"issue":"9463","key":"384_CR127","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947\u2013954","journal-title":"Lancet"},{"issue":"5","key":"384_CR128","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1474-4422(11)70073-4","volume":"10","author":"O Rascol","year":"2011","unstructured":"Rascol O et al (2011) A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 10(5):415\u2013423","journal-title":"Lancet Neurol"},{"issue":"4","key":"384_CR129","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1089\/cap.2006.16.404","volume":"16","author":"S Rubinstein","year":"2006","unstructured":"Rubinstein S et al (2006) Placebo-controlled study examining effects of selegiline in children with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol 16(4):404\u2013415","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"384_CR130","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/14656566.2019.1612877","volume":"20","author":"M Ryan","year":"2019","unstructured":"Ryan M, Eatmon CV, Slevin JT (2019) Drug treatment strategies for depression in Parkinson disease. Expert Opin Pharmacother 20(11):1351\u20131363","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"384_CR131","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/sj.bjp.0706355","volume":"146","author":"Y Sagi","year":"2005","unstructured":"Sagi Y, Drigues N, Youdim MB (2005) The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. Br J Pharmacol 146(4):553\u2013560","journal-title":"Br J Pharmacol"},{"issue":"1","key":"384_CR132","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF et al (2016) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol 36(1):77\u201381","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"384_CR133","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jnc.13116","volume":"134","author":"H Sano","year":"2015","unstructured":"Sano H, Murata M, Nambu A (2015) Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson\u2019s disease. J Neurochem 134(2):371\u2013381","journal-title":"J Neurochem"},{"key":"384_CR134","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.brainres.2015.04.043","volume":"1620","author":"R Santhanasabapathy","year":"2015","unstructured":"Santhanasabapathy R, Sudhandiran G (2015) Farnesol attenuates lipopolysaccharide-induced neurodegeneration in Swiss albino mice by regulating intrinsic apoptotic cascade. Brain Res 1620:42\u201356","journal-title":"Brain Res"},{"issue":"6","key":"384_CR135","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1111\/j.1471-4159.2008.05326.x","volume":"105","author":"E Sanz","year":"2008","unstructured":"Sanz E et al (2008) Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells. J Neurochem 105(6):2404\u20132417","journal-title":"J Neurochem"},{"issue":"2","key":"384_CR136","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1468-1331.2012.03840.x","volume":"20","author":"AH Schapira","year":"2013","unstructured":"Schapira AH et al (2013) Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson\u2019s disease. Eur J Neurol 20(2):271\u2013280","journal-title":"Eur J Neurol"},{"issue":"15","key":"384_CR137","doi-asserted-by":"publisher","first-page":"e1474","DOI":"10.1212\/WNL.0000000000008239","volume":"93","author":"LS Schneider","year":"2019","unstructured":"Schneider LS et al (2019) Low-dose ladostigil for mild cognitive impairment: a phase 2 placebo-controlled clinical trial. Neurology 93(15):e1474\u2013e1484","journal-title":"Neurology"},{"issue":"6","key":"384_CR138","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/jnc.12686","volume":"129","author":"J Segura-Aguilar","year":"2014","unstructured":"Segura-Aguilar J et al (2014) Protective and toxic roles of dopamine in Parkinson\u2019s disease. J Neurochem 129(6):898\u2013915","journal-title":"J Neurochem"},{"issue":"10","key":"384_CR139","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40263-013-0097-3","volume":"27","author":"KI Shulman","year":"2013","unstructured":"Shulman KI, Herrmann N, Walker SE (2013) Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 27(10):789\u2013797","journal-title":"CNS Drugs"},{"issue":"3","key":"384_CR140","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J et al (1994) Alterations in glutathione levels in Parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36(3):348\u2013355","journal-title":"Ann Neurol"},{"issue":"3","key":"384_CR141","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/154596830101500305","volume":"15","author":"J Sivenius","year":"2001","unstructured":"Sivenius J et al (2001) Selegiline treatment facilitates recovery after stroke. Neurorehabil Neural Repair 15(3):183\u2013190","journal-title":"Neurorehabil Neural Repair"},{"issue":"1","key":"384_CR142","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamaneurol.2014.2472","volume":"72","author":"KM Smith","year":"2015","unstructured":"Smith KM, Eyal E, Weintraub D (2015) Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 72(1):88\u201395","journal-title":"JAMA Neurol"},{"issue":"48","key":"384_CR143","doi-asserted-by":"publisher","first-page":"17120","DOI":"10.1523\/JNEUROSCI.2091-12.2012","volume":"32","author":"A Soliman","year":"2012","unstructured":"Soliman A et al (2012) Convergent effects of acute stress and glucocorticoid exposure upon MAO-A in humans. J Neurosci 32(48):17120\u201317127","journal-title":"J Neurosci"},{"issue":"15","key":"384_CR144","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.1073\/pnas.0710626105","volume":"105","author":"SY Son","year":"2008","unstructured":"Son SY et al (2008) Structure of human monoamine oxidase A at 2.2-\u00c5 resolution: the control of opening the entry for substrates\/inhibitors. Proc Natl Acad Sci U S A 105(15):5739\u20135744","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"384_CR145","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.expneurol.2009.11.018","volume":"221","author":"PK Sonsalla","year":"2010","unstructured":"Sonsalla PK et al (2010) The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol 221(2):329\u2013334","journal-title":"Exp Neurol"},{"issue":"2","key":"384_CR146","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/mus.26335","volume":"59","author":"JM Statland","year":"2019","unstructured":"Statland JM et al (2019) Rasagiline for amyotrophic lateral sclerosis: a randomized, controlled trial. Muscle Nerve 59(2):201\u2013207","journal-title":"Muscle Nerve"},{"key":"384_CR147","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2147\/DDDT.S77749","volume":"10","author":"F Stocchi","year":"2016","unstructured":"Stocchi F, Torti M (2016) Adjuvant therapies for Parkinson\u2019s disease: critical evaluation of safinamide. Drug Des Devel Ther 10:609\u2013618","journal-title":"Drug Des Devel Ther"},{"issue":"7 Suppl 2","key":"384_CR148","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1212\/WNL.67.7_suppl_2.S24","volume":"67","author":"F Stocchi","year":"2006","unstructured":"Stocchi F et al (2006) Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 67(7 Suppl 2):S24\u2013S29","journal-title":"Neurology"},{"issue":"3","key":"384_CR149","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00259-016-3510-6","volume":"44","author":"S Sturm","year":"2017","unstructured":"Sturm S et al (2017) Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer\u2019s disease and elderly controls after oral administration of sembragiline. Eur J Nucl Med Mol Imaging 44(3):382\u2013391","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"384_CR150","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00702-018-1853-9","volume":"125","author":"E Szoko","year":"2018","unstructured":"Szoko E et al (2018) Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson\u2019s disease. J Neural Transm (Vienna) 125(11):1735\u20131749","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"384_CR151","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/BF00216016","volume":"91","author":"PN Tariot","year":"1987","unstructured":"Tariot PN et al (1987) Cognitive effects of L-deprenyl in Alzheimer\u2019s disease. Psychopharmacology 91(4):489\u2013495","journal-title":"Psychopharmacology"},{"key":"384_CR152","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejmech.2018.01.003","volume":"145","author":"AC Tripathi","year":"2018","unstructured":"Tripathi AC et al (2018) Privileged scaffolds as MAO inhibitors: retrospect and prospects. Eur J Med Chem 145:445\u2013497","journal-title":"Eur J Med Chem"},{"issue":"6","key":"384_CR153","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.brainresbull.2011.05.001","volume":"85","author":"GK Ulusoy","year":"2011","unstructured":"Ulusoy GK et al (2011) Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson\u2019s disease. Brain Res Bull 85(6):380\u2013384","journal-title":"Brain Res Bull"},{"issue":"6","key":"384_CR154","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1021\/bi7021377","volume":"47","author":"AK Upadhyay","year":"2008","unstructured":"Upadhyay AK et al (2008) Determination of the oligomeric states of human and rat monoamine oxidases in the outer mitochondrial membrane and octyl beta-D-glucopyranoside micelles using pulsed dipolar electron spin resonance spectroscopy. Biochemistry 47(6):1554\u20131566","journal-title":"Biochemistry"},{"issue":"1","key":"384_CR155","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/ars.2011.4373","volume":"18","author":"C Villeneuve","year":"2013","unstructured":"Villeneuve C et al (2013) p53-PGC-1alpha pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. Antioxid Redox Signal 18(1):5\u201318","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"384_CR156","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/138945012799499794","volume":"13","author":"O Weinreb","year":"2012","unstructured":"Weinreb O et al (2012) Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer\u2019s disease treatment. Curr Drug Targets 13(4):483\u2013494","journal-title":"Curr Drug Targets"},{"key":"384_CR157","first-page":"61","volume":"48","author":"S Yasar","year":"1996","unstructured":"Yasar S, Goldberg JP, Goldberg SR (1996) Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J Neural Transm Suppl 48:61\u201373","journal-title":"J Neural Transm Suppl"},{"issue":"1","key":"384_CR158","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1124\/jpet.105.096263","volume":"317","author":"S Yasar","year":"2006","unstructured":"Yasar S et al (2006) Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(\u2212)-deprenyl]. J Pharmacol Exp Ther 317(1):387\u2013394","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"384_CR159","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1096\/fj.05-4910fje","volume":"20","author":"M Yogev-Falach","year":"2006","unstructured":"Yogev-Falach M et al (2006) A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 20(12):2177\u20132179","journal-title":"FASEB J"},{"issue":"Suppl 1","key":"384_CR160","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1016\/S1353-8020(11)70047-5","volume":"18","author":"MB Youdim","year":"2012","unstructured":"Youdim MB (2012) M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Parkinsonism Relat Disord 18(Suppl 1):S151\u2013S154","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"384_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5607\/en.2013.22.1.1","volume":"22","author":"MB Youdim","year":"2013","unstructured":"Youdim MB (2013) Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp Neurobiol 22(1):1\u201310","journal-title":"Exp Neurobiol"},{"issue":"4","key":"384_CR162","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7","author":"MB Youdim","year":"2006","unstructured":"Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295\u2013309","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl 1","key":"384_CR163","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/S1353-8020(13)70032-4","volume":"20","author":"MB Youdim","year":"2014","unstructured":"Youdim MB et al (2014) Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson\u2019s disease. Parkinsonism Relat Disord 20(Suppl 1):S132\u2013S136","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"384_CR164","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11307-018-1165-3","volume":"20","author":"F Zanderigo","year":"2018","unstructured":"Zanderigo F et al (2018) [(11)C]Harmine binding to brain monoamine oxidase A: test-retest properties and noninvasive quantification. Mol Imaging Biol 20(4):667\u2013681","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"384_CR165","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/jcbfm.2014.157","volume":"34","author":"P Zanotti-Fregonara","year":"2014","unstructured":"Zanotti-Fregonara P, Bottlaender M (2014) [11C]befloxatone distribution is well correlated to monoamine oxidase A protein levels in the human brain. J Cereb Blood Flow Metab 34(12):1951\u20131952","journal-title":"J Cereb Blood Flow Metab"},{"issue":"12","key":"384_CR166","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1097\/MNM.0000000000000196","volume":"35","author":"P Zanotti-Fregonara","year":"2014","unstructured":"Zanotti-Fregonara P et al (2014) Imaging of monoamine oxidase-A in the human brain with [11C]befloxatone: quantification strategies and correlation with mRNA transcription maps. Nucl Med Commun 35(12):1254\u20131261","journal-title":"Nucl Med Commun"},{"issue":"1","key":"384_CR167","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1471-4159.2005.03340.x","volume":"95","author":"H Zheng","year":"2005","unstructured":"Zheng H et al (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95(1):68\u201378","journal-title":"J Neurochem"},{"issue":"12","key":"384_CR168","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s11064-010-0293-1","volume":"35","author":"H Zheng","year":"2010","unstructured":"Zheng H, Fridkin M, Youdim MB (2010) Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer\u2019s disease. Neurochem Res 35(12):2117\u20132123","journal-title":"Neurochem Res"},{"issue":"1","key":"384_CR169","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0006-8993(01)02935-3","volume":"917","author":"Y Zhou","year":"2001","unstructured":"Zhou Y, Zhao ZQ, Xie JX (2001) Effects of isatin on rotational behavior and DA levels in caudate putamen in Parkinsonian rats. Brain Res 917(1):127\u2013132","journal-title":"Brain Res"},{"issue":"17","key":"384_CR170","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1016\/j.bmc.2018.08.024","volume":"26","author":"S Zhou","year":"2018","unstructured":"Zhou S, Chen G, Huang G (2018) Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase. Bioorg Med Chem 26(17):4863\u20134870","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"384_CR171","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0033-3182(85)72877-0","volume":"26","author":"S Zisook","year":"1985","unstructured":"Zisook S (1985) A clinical overview of monoamine oxidase inhibitors. Psychosomatics 26(3):240\u2013251","journal-title":"Psychosomatics"}],"container-title":["Handbook of Experimental Pharmacology","Reactive Oxygen Species"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2020_384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T02:11:02Z","timestamp":1649815862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2020_384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030685096","9783030685102"],"references-count":171,"URL":"https:\/\/doi.org\/10.1007\/164_2020_384","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"28 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}